UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Inadequate retirement planning can jeopardize your future. Learn to spot the warning signs to ensure your retirement is secure.
15,144 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
February data show a modest uptick in existing-home sales, but the market faces spring headwinds from affordability p...
The Jets ETF has breached critical chart support, suggesting airline stocks face risks beyond rising fuel costs. Tech...
Oil-driven volatility keeps the S&P 500 near unchanged on March 11, 2026, as traders weigh supply risks and central-b...
A large institutional stake in Enviri sparks questions about the company’s trajectory. This article breaks down what ...
Solana is trading in a narrow band as a key indicator points to a potential breakout. Analysts caution that volatilit...
Palantir stock isn't cheap, but its AI-driven data platform and strong government foothold create a long‑term thesis ...
A federal judge blocked DOJ subpoenas aimed at Fed Chair Powell over a congressional hearing on the central bank’s HQ...
Could XRP slip below $2 by 2027? This guide breaks down the three big hurdles, explains why a lower price is plausibl...
Micron Technology expands in Taiwan by acquiring Powerchip's P5 site, boosting DRAM and HBM capacity and setting up a...
Zoom's post-pandemic growth trajectory remains uncertain as investors weigh AI opportunities and competition. This pi...
Bitcoin faces a pivotal test as Moody’s recession odds rise toward a historic point. Macro signals suggest crypto cou...